twitter google

Peanut Allergy Treatment On The Horizon; FDA Approval Needed


Peanut allergies are running rapid in today’s society, affecting most North American schools when it comes to home lunches, baked goods entering the classroom, and class snacks. As some people’s allergies are literally a threat to their existence, with traces or smells of peanuts being deadly, it can be hard to live a normal life for those with the allergy, and a struggle to accommodate loved ones for those even without the allergy.

There is some good news on the horizon! A treatment has been recently developed to aid those who have to deal with peanut allergies, as it can be challenging to distinguish food items that are safe to eat.

Medical News Today reported that the treatment has been crafted by worldwide experts stemming from a variety of research institutions, with a goal to help those who are allergic to peanuts build up a tolerance so that they can handle any potential (and accidental) exposures without any issues.

In fact, a study was recently conducted to test just how effective this oral peanut allergy treatment, dubbed AR101, could be. Derived from peanut protein, the study team worked with individuals ranging from four to 55 years in age that have a peanut allergy. While most participants fell between the ages of four and 17, these individuals went through an oral food challenge, so the researchers could understand the severity around their allergic reactions.

Two-thirds of all participants took the AR101, while one-third were given placebo. Each of the individuals were given their assigned dosages daily, while slightly increasing amounts each day, and continued with this during the course of the study. By the end of the research, 80% of the individuals hit a daily maintenance dose, which equaled out to a peanut. The team reviewed significant increases in participants’ tolerance around peanuts, with two-thirds of the individuals who participated in the study able to tolerate the amount equal to two peanuts each day, after about nine to twelve months of participating in the treatment; half were able to tolerate equal amounts of four peanuts.

Additionally, individuals also stated they saw much less side effects during the study. Approximately six percent of those who participated experienced gastrointestinal side effects, causing them to leave the study, and close to one-third of them reported mild side effects.

It’s important to note that this certainly doesn’t mean that those who suffer from these types of allergies will be able to eat peanuts freely; however, it is certainly a breakthrough for this demographic, and does add hope for many when it comes to accidental peanut exposures.

The U.S. Food and Drug Administration (FDA) will be hopefully reviewing the treatment soon and it could potentially be widely available near the latter of 2019.






New Articles